D.C.'s Vanda Pharmaceuticals battling FDA on multiple fronts
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic competition to battles over getting more drugs to market.
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Vanda Pharmaceuticals seeks FDA nod for motion sickness drug
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
ETF Daily News5d
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com
Vanda Pharmaceuticals stock opened at $4.69 on Wednesday. Vanda Pharmaceuticals has a 1-year low of $3.61 and a 1-year high of $6.75. The firm has a market capitalization of $273.47 million, a PE ...
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab
Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.
Vanda Pharmaceuticals accepts FDA opportunity for a hearing in tradipitant NDA
Vanda Pharmaceuticals (VNDA) provided an update on the tradipitant development program. Gastroparesis is a serious digestive disorder of the ...
ETF Daily News21d
Vanda Pharmaceuticals (NASDAQ:VNDA) Given Buy Rating at HC Wainwright
Vanda Pharmaceuticals stock opened at $4.51 on Tuesday. The business’s 50-day simple moving average is $4.81 and its 200-day simple moving average is $5.03. The firm has a market capitalization ...